Table 5.
Dependence of genotypes and frequencies of XRCC2 and XRCC3 gene polymorphism alleles on tumor stage in triple-negative breast cancer patientsa
| Stageb | Triple-negative breast cancer patients | |||
|---|---|---|---|---|
| I (n = 20) | II + III (n = 50) | OR (95 % CI)c | p d | |
| XRCC2 Arg188His | ||||
| 188Arg/Arg | 4 (20) | 14 (28) | 1.00 Ref | |
| 188Arg/His | 14 (70) | 20 (40) | 2.45 (0.66–9.02) | 0.289 |
| 188His/His | 2 (10) | 16 (32) | 1.09 (0.29–4.08) | 0.588 |
| 188Arg | 22 (55) | 48 (48) | 1.00 Ref | |
| 188His | 18 (45) | 52 (52) | 0.76 (0.36–1.57) | 0.571 |
| XRCC3 Thr241Met | ||||
| 241Thr/Thr | 4 (20) | 15 (30) | 1.00 Ref | |
| 241Thr/Met | 14 (70) | 21 (42) | 2.50 (0.68–9.11) | 0.267 |
| 241Met/Met | 2 (10) | 14 (28) | 0.53 (0.08–3.39) | 0.417 |
| 241Thr | 22 (55) | 51 (51) | 1.00 Ref | |
| 241Met | 18 (45) | 49 (49) | 0.85 (0.40–1.77) | 0.806 |
a n = 70
baccording to scarff–bloom–Richardson criteria
ccrude odds ratio (OR), 95 % CI = confidence interval at 95 %
dchi square